State of Play

We are experiencing a “golden twenties” in science with breakthrough therapies in rare diseases, oncology, cell and gene therapy, and regenerative medicine, but…

Biotech and Big Pharma will bring a record number of NCEs and biologics to market
Precision-medicine at the core
Drug development model essentially unchanged since 1960ies intro of RCTs and evidence-based medicine
Prices for new drugs keep going up
Combined budget impact will put pressure on government and private payers

Opportunity to re-purpose and improve established therapies with novel drug design and delivery systems

Improve established therapies with novel drug design and delivery systems
Re-purpose known drugs based on new science; design new patentable molecules and delivery systems

Opportunity to transform drug development leveraging digital solutions

Established biopharma is conservative and without incentives to cut development costs
Many tech companies, incl start-ups, have individually novel digital solutions but fail to evolve into a decentralised ecosystem
Patient-centricity still not at the centre of the biopharma development model

Corporate Philosophy

Health Minister to Pharma CEO: “You need to be disrupted”

Conversation among Finance Ministers at OECD meeting: “We need Uberification of pharma”

Our beliefs

Alongside Big Pharma delivering from the frontiers of science, there is a need for a complementary model
The drug development model will not be changed through Schumpeter-like creative destruction; it has to change from within
Transformation of drug development can only take place taking forward real assets (molecules), not through wholesale A-Z transformation platforms or programs
By making drug development go faster and at lower cost, we can help make drugs more affordable

Our plan

Using re-purposing and novel drug design and delivery systems to obtain patented assets
Assembling a decentralised ecosystem of big and small entrepreneurs to digitally transform the drug development model through virtual clinical trials and patient engagement through the whole life cycle
Keep assets together to leverage platform and ecosystem while seeking development funding from different biopharma and VCs, with different funding models.